News
Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback